Prophylactic Treatment With Oseltamivir

University Medical Centre Ljubljana

Status: Completed

Conditions: Influenza, Human

Treatments: Drug: Oseltamivir Oral Capsule for 10 days post-exposure; Drug: Oseltamivir Oral Capsule for 5 days post-exposure

Study type: Interventional

Funder types: Other

Identifiers

NCT03899571

Tamiflu 2019

Details and patient eligibility

About

The purpose of this study is to compare the efficacy of 5-day versus 10-day oseltamivir prophylactic treatment in patients who had been exposed to influenza.

Enrollment: 222 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18 years or older
• exposure to influenza during hospitalization
• risk factors for influenza complications
• consent for participation obtained

Exclusion criteria

• younger than 18 years
• hematological malignancy
• hospitalized in intensive care unit
• refusal to participate

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

222 participants in 2 patient groups

5 days

Active Comparator group

Description:

oral oseltamivir 75 mg once daily for 5 days post-exposure

Treatment:

Drug: Oseltamivir Oral Capsule for 5 days post-exposure

10 days

Active Comparator group

Description:

oral oseltamivir 75 mg once daily for 10 days post-exposure

Treatment:

Drug: Oseltamivir Oral Capsule for 10 days post-exposure